Home > Healthcare > Pharmaceuticals > Finished Drug Form > transthyretin amyloidosis treatment market
Get a free sample of Transthyretin Amyloidosis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Transthyretin Amyloidosis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting multi-pronged approaches to address the rising demand for new treatments and strengthen their market presence.
Prominent players operating in the transthyretin amyloidosis treatment industry are as mentioned below:
Some of the top transthyretin amyloidosis treatment companies are Acrotech Biopharma, LLC, AstraZeneca PLC, Astellas Pharma Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Prothena Biosciences Limited, Pfizer Inc., SOM Innovation Biotech, S.L.
North America accounted 37.6% revenue share of the transthyretin amyloidosis treatment industry in 2023 and is set to expand at a considerable growth rate through 2032 due to well-established healthcare infrastructure, and high awareness about rare diseases among healthcare professionals and patients.
The ATTR-CM segment generated USD 4.7 billion in revenue in 2023 and is estimated to grow at a notable CAGR from 2024-2032 owing to the rising advancements in diagnostics techniques that aid in timely intervention.
Transthyretin amyloidosis treatment industry was valued at USD 5.9 billion in 2023 and is poised to expand at 7.5% CAGR between 2024 and 2032 owing to the increasing prevalence of transthyretin amyloidosis, a rare genetic disorder, coupled with advancements in treatment options for rare diseases.